Supplementation of transport and freezing media with anti-apoptotic drugs improves ovarian cortex survival by Laurie Henry et al.
RESEARCH Open Access
Supplementation of transport and freezing
media with anti-apoptotic drugs improves
ovarian cortex survival
Laurie Henry1,2, Maïté Fransolet1, Soraya Labied1,2, Silvia Blacher1, Marie-Caroline Masereel1,2, Jean-Michel Foidart1,
Agnès Noel1, Michelle Nisolle1,2 and Carine Munaut1*
Abstract
Background: Ovarian tissue preservation is proposed to patients at risk of premature ovarian failure, but this
procedure still needs to be optimized. To limit injury during ovarian tissue cryopreservation, anti-apoptotic drugs were
added to the transport and freezing media of ovarian cortex tissue.
Methods: Sheep ovaries were transported, prepared and frozen in solutions containing vehicle or anti-apoptotic drugs
(Z-VAD-FMK, a pan-caspase inhibitor, or sphingosine-1-phosphate (S1P), a bioactive lipid). After the tissue was thawed,
the ovarian cortex was cultured for 2 or 6 days. Follicular quantification and morphological and proliferation analyses
were performed on histological sections.
Results: After 2 days of culture, S1P improved the quality of primordial follicles; higher densities of morphologically
normal and proliferative primordial follicles were found. Z-VAD-FMK displayed similar effects by preserving global
primordial follicular density, but this effect was evident after 6 days of culture. This drug also improved cell proliferation
after 2 and 6 days of culture.
Conclusions: Our results showed that the addition of S1P or Z-VAD-FMK to the transport and freezing media prior to
ovarian tissue cryopreservation improves primordial follicular quality and therefore improves global tissue survival. This
should ultimately lead to improved fertility restoration after auto-transplantation.
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Background
Currently, patients with cancer clearly benefit from ag-
gressive chemotherapy, radiotherapy and bone marrow
transplantation. However, these treatments can induce
premature ovarian failure (POF) in girls or young
women. Ovarian cryopreservation should be proposed to
these patients before they begin treatment. This proced-
ure has already allowed the birth of more than 40 babies
across the world [1–3], but it still needs to be optimized.
Indeed, ovarian cortex cryopreservation followed by
auto-transplantation after cancer remission affects the
quality of the ovarian tissue. The primordial follicular
reserve decreases, which consequently impairs the sur-
vival lifespan of the grafted tissue fragments, limiting the
possibility for procreation.
Ovarian transplantation is avascular, which results in
tissue ischemia over the 5 first days after grafting and is
sometimes associated with reperfusion injury [4, 5]. This
transient hypoxic period is followed by gradual oxygen-
ation, leading to reperfusion of the ovarian transplant.
This process represents the main origin of ischemia and
follicular loss [6, 7]. The freezing procedure also induces
tissue damage. In fact, slow freezing is the gold standard
for ovarian tissue cryopreservation. However, this tech-
nique is known to lead to tissue fibrosis [8] and to alter
the viability of both stromal and follicular cells within
the ovarian samples [9, 10]. Apoptosis also plays an im-
portant role in cryo-injuries, mainly by the activation
caspases and the Fas system [11–13]. Indeed, caspase
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activation was observed in frozen-thawed tissue with
preserved architecture [14].
Several anti-apoptotic drugs have already been proposed
to improve fertility preservation. They were studied along
with preventive treatment during oncologic therapy rather
than during the ovarian tissue cryopreservation process,
including during freezing or transplantation. Among
these drugs, imatinib, a kinase inhibitor that mainly
targets the ABL family members KIT and PDGFR,
protects ovarian tissue during chemotherapy by inhi-
biting cisplatin-induced Tap63-α phosphorylation [15].
Sphingosine-1-phosphate (S1P) is a bioactive lipid in
follicular fluid that has two interesting properties: it
is anti-apoptotic and pro-angiogenic [16]. In several
studies, S1P has been shown to protect the follicle re-
serve by decreasing apoptosis during chemotherapy
and radiotherapy [17–22].
On the other hand, anti-apoptotic drugs have been
used during the cryopreservation process to prevent the
activation of apoptotic pathways and subsequently im-
prove tissue survival during freezing and grafting. The
addition of Z-VAD-FMK, a pan-caspase inhibitor, to the
freezing and thawing media has been shown to decrease
the apoptosis rate and the number of days before the es-
trous cycle is resumed following auto-transplantation of
cryopreserved mouse ovaries [23]. S1P has also been
used in the vitrification media before the transplantation
of mouse ovaries and conferred significant protection of
primordial follicles after grafting [24, 25].
Anti-apoptotic drugs have also been evaluated during
tissue transplantation. In an auto-transplantation model
of fresh sheep ovarian fragments into the abdominal
wall, S1P did not show a beneficial effect [26]. However,
the use of the same drug in xenografts of fresh human
ovarian cortex in immunodeficient mice improved angio-
genesis and decreased follicular apoptosis [27].
Meanwhile, these anti-apoptotic drugs could have a
protective effect on ovaries during oncologic treatment
or transplantation in mice, but the use of these anti-
apoptotic drugs in vivo during oncologic treatment is
only possible in animal models. However, their use in
cryopreservation media alone appears to be safer and
could be applicable to humans.
In vitro culture of thawed ovarian tissue is an import-
ant approach to use to analyze tissue after the cryo-
preservation process because the integrity of the tissue
immediately after thawing may not reflect its true state
[10, 28, 29]. It also enables observation of the effects of
cryopreservation without transplantation.
The purpose of our study was to analyze and compare
the effects of two anti-apoptotic drugs, Z-VAD-FMK and
S1P, when added to the transport and freezing media for
sheep ovarian cortex pieces, on survival during in vitro
culture of the tissue immediately after thawing.
Methods
Ovarian tissue sampling
This study was approved by the Animal Ethics Committees
of the Universities of Liège and Namur. Our experimental
design is detailed in Fig. 1. Four ewes, 4 and 5 months old,
were obtained from the Ovine Research Center of Namur
University, and their ovaries were collected immediately
after the ewes were euthanized. The ovaries were cut into
2 pieces, and one piece of each ovary was immersed in
transport media composed of Leibovitz L-15 medium
(Lonza, Verviers, Belgium, BE12-700 F) supplemented with
10 % normal sheep serum (Hormonology Laboratory,
Belgium) and anti-apoptotic drugs. The anti-apoptotic
drugs included 10 μM Z-VAD-FMK (R&D, United
Kingdom, FMK001), which was diluted in DMSO, and
10 μM S1P (Biomol, Germany, Cay62570-10), which was
diluted in 0.3 M NaOH. In the control groups, the anti-
apoptotic drugs were replaced with the appropriate vehi-
cles, namely, DMSO for Z-VAD-FMK and NaOH for S1P.
The ovaries were further prepared by removing medul-
lary tissue, and the cortex was cut in 2-mm-diameter
round pieces with a disposable biopsy punch (Miltex,
Germany, 33-31-P/25). Twenty-four pieces per condition
were obtained for the cryopreservation process, and 6 were
immediately fixed in 4 % formaldehyde and embedded in
paraffin for histological analysis (fresh condition, F).
Throughout the entire process of ovarian cortex prepar-
ation, the ovaries were kept at 4 °C.
Freezing and thawing of ovarian tissue
Cryopreservation was performed by slow freezing ac-
cording to the technique first described by Gosden
[30, 31]. Z-VAD-FMK (10 μM) or S1P (10 μM) was
added to the cryopreservative medium. For thawing,
cryovial tubes were removed from liquid nitrogen, left
at room temperature for 2 min and then immersed in
a 37 °C water bath at until the tissue was completely
thawed. The ovarian pieces were subsequently washed
three times in 37 °C culture medium without serum
to remove the cryoprotective agents. Each wash lasted
for 5 min. For each group, 6 pieces were fixed in 4 %
formaldehyde and embedded in paraffin for histo-
logical analysis (frozen-thawed condition, F-T).
In vitro culture of ovarian pieces
Thawed ovarian fragments were individually trans-
ferred to a Cellstar® 96-well plate U-Bottom (Greiner
Bio-One, Italy, 650 185). Each well was filled with
100 μL of Dulbecco’s Modified Eagle Medium (Life
Technologies, Belgium, 31053-028) supplemented with
200 mM L-Glutamine (Life Technologies, Belgium,
25030024), 100 μg/ml ascorbic acid, 1 μl/ml Insulin-
Transferrin-Selenium solution (Life Technologies,
Belgium, 41400-045), 1 μl/ml penicillin-streptomycin
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(10,000 U/mL; Life Technologies, Belgium, 15140-122), 25
mIU/ml recombinant FSH (Merck, Germany, Gonal-F®)
and 5 % normal sheep serum. The tissue fragments were
cultured for 2 (D2 condition) or 6 days (D6 condition) at
37 °C in a humidified incubator with 5 % CO2 and 5 % O2
as described by Sanfilippo [28]. The ovarian punches were
fixed in 4 % formaldehyde, embedded in paraffin and cut
into 5-μm serial sections for histological analysis.
Histological analysis
Virtual images were acquired as previously described
with an automatic digital slide scanner NanoZoomer
2.0HT (Hamamatsu, Belgium) [32].
To limit the effect of the heterogeneous distribution
of the follicular pool within the ovarian cortex, 12
sections per ovarian piece, which covered the entire
fragment, were analyzed as previously described [33].
Follicular quantification and morphological evaluation
were performed as previously described [34]. Briefly,
primordial follicles were considered degenerated if
they contained disorganized granulosa cells, shrunken
ooplasm or pyknotic oocytes.
Cell proliferation was evaluated by Ki-67 immunola-
beling using MIB-1, a monoclonal mouse anti-human
Ki-67 antigen clone (Dako, Denmark, M7240), at 1/100.
Dako EnVision + HRP anti-mouse (Dako, Denmark,
K4001) and DAB+ (K3468, Dako, Belgium) were used to
view the immunolabeling.
Follicles were considered proliferative if at least one
Ki-67-positive granulosa cell was observed at ×200 mag-
nification (Leica ICC50 HD Camera, Belgium).
Stromal cell proliferation was automatically quantified
using the image analysis toolbox of MATLAB 8.1.0.604
(R2013a) (MathWorks, Inc.). Because cell detection was
mainly based on color segmentation, contrast was first
enhanced by determining the excess of the red compo-
nent (two times red value minus blue value minus green
value). Then, based on the enhanced red component of
the resulting color image, binary images of the cells (i.e.,
pixels belonging to cells were assigned an intensity of 1,
whereas background pixels were assigned an intensity of
0) were obtained using an automatic entropy threshold
[35]. To eliminate small artifacts, morphological filters
[36] were applied on the resultant images. Binary images
of the total tissue sections were obtained by applying an
appropriate threshold to the blue component of the im-
ages. Lastly, cell density was defined as the area occu-
pied by cells divided by the total area of the section.
Statistical analyses
After the outcomes were logarithmically transformed, a
linear mixed model was fit to the data to test for differ-
ences between the treatments and the number of days in
culture. In this model, the ovarian fragment was intro-
duced as a random factor. To correct for multiple com-
parisons and to avoid type I errors, the level of statistical
significance was set at p = 0.01. Calculations were always
Fig. 1 Study design describing the different conditions. Eight ovaries were cut into 2 parts and distributed among the four groups of transport
media containing anti-apoptotic drugs (10 μM S1P or 10 μM Z-VAD-FMK) or vehicle (Control (CT); NaOH or DMSO). After the tissue was prepared,
the ovarian cortex was cut into pieces with a biopsy punch to obtain similarly sized fragments (diameter of 2 mm). These pieces (24 punches per
group), which were from different ovaries, were mixed and then randomly assigned to processing for the fresh histological analyses (6 punches)
or to freezing (6 punches). After freezing and thawing, 6 punches were fixed (F-T), and the others were cultured for 2 or 6 days (D2 or D6). For
histology, each entire punch was cut, and 12 sections were analyzed for follicular density and morphological assessment, whereas 3 sections were
analyzed for proliferation
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carried out on the maximum amount of data available.
The data analysis was carried out using the SAS (version
9.3 for Windows) statistical package.
Results
Follicular density
The investigation of follicular density in H&E stained
sections revealed a very low number of primary and sec-
ondary follicles, which precluded statistical analysis. The
analysis was therefore performed only on primordial
follicles.
Evaluation of the primordial follicular density demon-
strated that supplementation with S1P did not com-
pletely prevent primordial follicular loss during culture.
Nevertheless, follicular density was higher in the S1P-
treated group compared to the control group (Fig. 2b,
Table 1 and Additional file 1: Tables S1 and S2).
Z-VAD-FMK significantly decreased follicular loss after
cryopreservation compared to vehicle (Fig. 2b). In-
deed, post-thawing follicular density was maintained
after up to 6 days of culture after Z-VAD-FMK treat-
ment, while there was a constant decrease in the con-
trol group (Table 1 and Additional file 1: Table S1).
Therefore, after 6 days of culture, more follicles were
observed in the treated group than in the control
group (Fig. 2a and Additional file 1: Table S2).
Follicular quality
Morphology of primordial follicles
Primordial follicle morphology was evaluated in H&E
sections (Fig. 3a). Morphologically normal follicles were
distinguished from degenerated follicles. This analysis
showed that the freezing process decreased the density
of morphologically normal primordial follicles. This re-
duction continued progressively throughout the culture
duration.
Supplementation with S1P preserved follicular morph-
ology; compared to the density of normal follicles
found in the control tissues, the density of normal
follicles was greater in the fresh tissue and after 2 days
of culture, whereas this difference faded after 6 days
in culture (Fig. 3b, Table 2 and Additional file 1: Tables S3
and S4).
Compared to the effects of S1P, the effects of Z-
VAD-FMK seemed to occur later. Compared to ve-
hicle, Z-VAD-FMK significantly preserved the density
of morphologically normal follicles between 2 and
6 days of culture (Fig. 3c, Table 2 and Additional file
1: Table S3). Therefore, the density of normal primor-
dial follicles that was observed after 6 days of culture
Fig. 2 Analysis of total primordial follicle density. The number of primordial follicles (log(number / mm2 + 1)) in the ovarian fragments in the
different conditions, fresh (F), frozen-thawed (F-T), and after 2 (D2) and 6 days (D6) of culture, was quantified and compared between the control
groups and the a 10 μM S1P and b 10 μM Z-VAD-FMK groups. *** p < 0.0001
Table 1 Primordial follicle density (number of primordial
follicles/mm2 (log(X + 1))
F F-T D2 D6
Control NaOH 1.4111 1.7764 0.6482** 0.1584***
10 μM S1P 1.6012 1.6200 0.9070** 0.4799***
Control DMSO 1.6609 1.3464* 1.0350** 0.4099***
10 μM Z-VAD-FMK 1.6209 1.2348* 1.1145 0.9636
*p < 0.01 between the frozen-thawed (FT) and the fresh (F) tissue
**p < 0.01 between tissue after 2 days of culture (D2) and frozen-thawed tissue
***p < 0.01 between 6 (D6) and 2 days of culture
All p values are provided in Additional file 1: Tables S1 and S2
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was higher in the treated group than in the control
group (Fig. 3c and Additional file 1: Table S4).
Granulosa cell proliferation
Granulosa cell proliferation, as analyzed by Ki-67 im-
munostaining, was used as a second marker of follicular
health (Figs. 4 and 5). Granulosa cells that were associ-
ated with healthy follicles were able to proliferate as
soon as 2 days of culture; thereafter, proliferation
seemed to decrease, as observed after 6 days (Fig. 6a
and b). Supplementation with anti-apoptotic drugs re-
sulted in a higher density of proliferative granulosa cells
Fig. 3 Analysis of primordial follicle morphology. a Illustration of primordial follicles considered morphologically normal (arrows) or abnormal
(arrowheads). Abnormal primordial follicles were characterized by disorganized granulosa cells, shrunken ooplasm and/or pyknotic oocytes. The
density of morphologically normal primordial follicles (log(number / mm2 + 1)) in the ovarian fragments under the different conditions, fresh (F),
frozen-thawed (F-T), and after 2 (D2) and 6 days (D6) of culture, was quantified and compared between the control group and the b 10 μM S1P
and c 10 μM Z-VAD-FMK groups. Scale bar: 250 μm. * p < 0.01. *** p < 0.0001
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(which were defined as proliferative primordial follicles)
after 2 days of culture with S1P (Figs. 4 and 6a and
Additional file 1: Table S5) and after 6 days of culture
with Z-VAD-FMK (Figs. 5 and 6b and Additional file 1:
Table S5), confirming the beneficial effect of the 2 anti-
apoptotic drugs on follicular health.
Cell proliferation
Global proliferation (granulosa and stroma) in ovarian
punches, as revealed by Ki-67 immunostaining was used
to evaluate the quality of the ovarian tissue. The prolifer-
ation of follicles together with the presence of mitosis in
granulosa cells serves as an indication of the viability of
follicles that are grown in culture. These measures also
indicate that frozen/thawed follicles can remain func-
tional over the culture period.
Supplementation with S1P did not affect proliferation
(Fig. 6c and Additional file 1: Table S6), whereas increased
proliferative cell density was found after 2 and 6 days
of culture after supplementation with Z-VAD-FMK
compared to vehicle treatment, demonstrating that
this anti-apoptotic drug improved tissue survival
(Fig. 6d, Additional file 1: Table S6).
Discussion
In the present study, ovarian tissues treated with anti-
apoptotic drugs before and during cryopreservation
showed significantly higher primordial follicle density
and quality after 2 or 6 days of culture. Two different
drugs, Z-VAD-FMK and SIP, were added in the trans-
port and freezing media used for the sheep ovarian
tissue. For SIP, these positive effects were evident
over the short term, after 2 days in culture, whereas
for Z-VAD-FMK, they were evident over the long
term, after 6 days in culture. Our results demon-
strated that Z-VAD-FMK supplementation during
transport and slow freezing improved the survival of
the ovarian tissue, as demonstrated by a higher rate
of cell proliferation after 2 and 6 days of culture
compared to that of the control. In our study, pri-
mary and more mature follicles were not analyzed
due to their low numbers, and transitional follicles were
considered primordial. Only immature follicles enable sus-
tainable restoration of ovarian function after transplant-
ation because antral follicles are not cryoresistant [2].
Ovarian tissue cryopreservation followed by auto-
transplantation is a promising method that has produced
good results. However, this technique still needs to be
Table 2 Morphologically normal primordial follicle density
(number of primordial follicles/mm2 (log(X + 1))
F F-T D2 D6
Control NaOH 1.0316 1.2435 0.3161** 0.03793***
10 μM S1P 1.3735 1.0081* 0.6635** 0.07230***
Control DMSO 1.2810 0.7495* 0.4699** 0.1374***
10 μM Z-VAD-FMK 1.2200 0.7870* 0.5263** 0.3946
*p < 0.01 between the frozen-thawed (FT) and the fresh (F) tissue
**p < 0.01 between tissue after 2 days of culture (D2) and frozen-thawed tissue
***p < 0.01 between 6 (D6) and 2 days of culture
All p values are provided in Additional file 1: Tables S3 and S4
Fig. 4 Illustration of proliferative cells when treated with S1P. Proliferative granulosa and stromal cells, immunostained with a Ki67 AB, in ovarian
fragment after 2 and 6 days of culture in the NaOH control group (respectively a and c) and the 10 μM S1P group (respectively b and d). Scale
bar: 50 μm
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improved, including both the freezing and transplant-
ation processes. Indeed, significant apoptotic loss of
primordial follicles occurs during cryopreservation
[13, 37]. In humans, the use of anti-apoptotic drugs
within the site of transplantation is technically difficult
and also raises ethical issues. We therefore decided to
treat ovarian samples only ex vivo. Our aim was to assess
if supplementation of the transport, preparation and cryo-
preservation media before transplantation of the ovarian
cortex could be beneficial. The in vitro tissue culture sys-
tem that was utilized was previously used by others to test
the effects of drugs on ovarian tissue survival [10, 28, 29]
and allowed us to evaluate tissue and follicle viability and
integrity. Indeed, the analysis of cortex samples immedi-
ately after thawing may not reflect their real state [10, 28].
We therefore performed tissue culture for up to 6 days
after the tissue was thawed.
The potential benefit of anti-apoptotic drugs such as
Z-VAD-FMK was based on previous studies that de-
scribed significant apoptotic loss of primordial follicles
during slow freezing-based cryopreservation [13, 37]
and by studies that described the role of caspases in the
activation of apoptosis in granulosa cells via activation
of the Fas system [12, 14]. This anti-apoptotic drug was
already identified as a cryoprotective agent that im-
proves the recovery and the survival of cryopreserved
cells and vitrified porcine embryos [11, 38]. The bio-
active lipid, S1P, has been demonstrated to limit ovarian
toxicity during both chemo- and radiotherapy [17–21]
(see Additional file: 2 FigureS1) . Addition of S1P in
granulosa cells culture has shown to prevent apoptosis
induced by oxidative stress [39]. Its protective effects
during ovarian tissue cryopreservation and transplant-
ation are more controversial. When used during auto-
transplantation of fresh ovine tissue, no beneficial effect
was observed [26]. The same effect was described when
SIP was added to the freezing media of whole ovine
ovaries [40] or to the culture media of ovarian tissue
after slow freezing or vitrification [41]. S1P supplemen-
tation during vitrification of mouse ovaries improved
the number of morphologically intact primordial folli-
cles present after grafting [24, 25]. In our study, S1P
did not preserve follicle density after cryopreservation
but did improve follicle morphology after transport
(fresh tissue) and after 2 days in culture, when in-
creased granulosa cell proliferation was detected. We
did not observe an S1P-mediated improvement in cell
proliferation. However, S1P has already been shown
to improve stromal cell proliferation, although these
effects were observed for a higher concentration of
S1P and after a different supplementation method
[27].
Conclusions
Our results showed that the addition of S1P or Z-
VAD-FMK to the transport and freezing media prior
to ovarian tissue cryopreservation improved primor-
dial follicular quality and therefore improved global
tissue survival.
Fig. 5 Illustration of proliferative cells when treated with Z-VAD-FMK. Proliferative granulosa and stromal cells, immunostained with a Ki67 AB, in
ovarian fragment after 2 and 6 days of culture in the DMSO control group (respectively a and c) and the 10 μM Z-VAD-FMK group (respectively
b and d). Scale bar: 50 μm
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However, the beneficial effects of these two com-
pounds over 2–6 days in culture do not necessarily
imply that this approach will improve engraftment
and/or maintenance of primordial follicle health after
transplantation. Eventually, it will be necessary to show
that this approach improves the potential for conception
by demonstrating normal follicular development. Simi-
larly, improved oocyte health and fertilization will need to
be demonstrated via healthy, live-born pregnancies and
other supporting in vivo experimental evidence. Thus, at
present, this model only provides a surrogate marker to
encourage additional work in this area.
Additional files
Additional file 1: Statistical analyses between the different
conditions and treatments. Table S1 and Table S2. Primordial follicular
density. Table S3 and Table S4. Density of morphologically normal
primordial follicules. Table S5. Density of proliferative granulosa cells
Fig. 6 Analysis of proliferative cells in the ovarian fragments. Primordial follicles containing proliferative granulosa cells (log(number/mm2 + 1))
in the ovarian fragments under the different conditions, fresh (F), frozen-thawed (F-T), and after 2 (D2) and 6 days (D6) of culture, were quantified
and compared between the control groups and the a 10 μM S1P and b 10 μM Z-VAD-FMK groups. All proliferative cells within the whole ovarian
fragment (log(number/mm2 + 1)) were quantified for the ovarian fragments treated with c 10 μM S1P or d 10 μM Z-VAD-FMK. Scale bar: 250 μm.
* p < 0.01. *** p < 0.0001
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between treatments. Table S6. Density of global proliferative cells
between treatments. (XLSX 38 kb)
Additional file 2: Figure S1. Cellular anti-apoptotic mechanisms of S1P
and Z-VAD-FMK. The effects of extracellular S1P are primarily mediated
through S1P receptors (mainly S1PR-1 and −3), which are G protein-
coupled receptors that activate the PI3K/Akt pathway. This activation
inhibits caspase activation and, consequently, inhibits the execution
of apoptosis in granulosa cells (Nakahara [39]). Z-VAD-FMK, which is
cell-permeable, is known to inhibit the activity of caspase-3, −8 and −9 by
binding to the catalytic sites of these caspases. Inhibition of these caspases
prevents the execution of apoptosis (Men [38]). (DOCX 1386 kb)
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